LONDON, UK / ACCESSWIRE / July 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Lannett Co., Inc. (NYSE: LCI), following which we have published a free report that can be viewed by signing up at The Philadelphia based Company announced on July 14, 2017, that it has received consent from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP) 2 mg/5 mL, the therapeutic equivalent to the reference standard drug, Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution USP) by Lyne Laboratories, Inc. The product was previously marketed under the brand name Periactin® Syrup, 2 mg/5 mL of Merck and Co., Inc. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on LCI. Go directly to your stock of interest and access today’s free coverage at:

According to IMS, the total US sales of Cyproheptadine Hydrochloride Syrup, 2 mg/5 ml, at Average Wholesale Price (AWP) was approximately $6 million for the 12 months ending in May 2017.

Cyproheptadine Hydrochloride Syrup Uses

The drug is used for the treatment of allergic reactions caused by seasonal allergies, food, blood or plasma. It is also used to treat mild, uncomplicated hives.

Approval Helped in Portfolio Expansion

Arthur Bedrosian, Chief Executive Officer of Lannett Co., exclaimed that the approval of Cyproheptadine Hydrochloride Syrup helped the company in expanding its portfolio of medications in liquid dosage form. He further expressed that through Lannett Co.’s wholly owned subsidiary, Silarx Pharmaceuticals, it develops and manufactures oral solution drug products, thereby differentiating Lannett from other generic drug companies. Oral solution products also act as key driver of Lannett Co.’s growth strategy, and the Company caters to the needs of the aging baby boomer population. Over the last two months, the Company has received six product approvals.

Approval of Other Drugs in 2017

As per the news releases, Lannett Co. received the approval for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg, the therapeutic equivalent to the reference listed drug, Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg, of Mikart, Inc, and Amantadine Hydrochloride Capsules USP, 100 mg, the therapeutic equivalent to the reference standard drug, Amantadine Hydrochloride Capsules USP, 100 mg, of Sandoz Pharmaceuticals, from FDA on June 26 and June 19, 2017, respectively.

On May 16, 2017, Lannett Co., also announced the approval of its ANDA for Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL), the therapeutic equivalent to the reference listed drug, Xyzal® Oral Solution, 2.5 mg/5 mL (0.5 mg/mL), of UCB Inc, from the FDA

About Lannett Co., Inc.

Lannett Co. develops, manufactures, and distributes high qualitygeneric prescription pharmaceutical products in tablet, capsule, and oral liquid forms to customers throughout the United States. Lannett markets its products primarily to drug wholesalers, retail drug chains, distributors, and government agencies. The Company was established in 1942.

Last Close Stock Review

On Friday, July 14, 2017, the stock closed the trading session at $22.70, climbing 6.57% from its previous closing price of $21.30. A total volume of 648.34 thousand shares has exchanged hands. Lannett’s stock price surged 22.37% in the last one month and 11.55% in the previous six months. Furthermore, since the start of the year, shares of the Company have gained 2.95%. The stock currently has a market cap of $792.91 million.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

Related Posts Plugin for WordPress, Blogger...